nach oben

Erschienen in:

25.09.2018 | Original articles

Transient elevation of high-sensitive troponin T after Cardioband implantation

verfasst von: M. M. Kreusser, MD, S. T. Pleger, MD, H. Abu Sharar, MD, N. A. Geis, MD, R. Bekeredjian, MD, H. A. Katus, MD, P. W. Raake, MD

Erschienen in: Herz | Ausgabe 6/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

The Cardioband system enables percutaneous surgical-like direct mitral valve annuloplasty and, thereby, repair of severe functional mitral valve regurgitation (MR) in patients with advanced systolic heart failure (HF) and dilation of the left ventricular (LV) annulus. Since the device is anchored by screws in the LV annulus, limited myocardial injury is likely to occur.

Methods and results

Five patients (Society of Thoracic Surgeons score: 2.7 ± 0.7%) with severe HF (LV ejection fraction [LVEF]: 17 ± 1%; LV end-diastolic diameter [LVEDD]: 71 ± 3 mm) were treated with the Cardioband (sizes C–F) receiving 14–17 screws in the LV annulus region. Myocardial injury was monitored by measuring high-sensitive cardiac troponin T (hsTnT) levels and by echocardiography. All patients showed significant periprocedural increase in hsTnT levels. Peak hsTnT concentration was reached between day 1 and day 6 (593 ± 141 pg/ml). None of the patients showed clinical signs of myocardial infarction, ST-segment elevation, new onset of deteriorated myocardial wall motion, or new ventricular tachycardia. hsTnT levels normalized in all patients after 14 days (hsTnT on day 0: 34 ± 6 pg/ml vs. hsTnT on day 14: 36 ± 6 pg/ml; p = 0.604). This nonischemic hsTnT kinetics was compared to a sixth patient who experienced proximal damage of the left circumflex artery (LCX) and ST-segment elevation during the Cardioband procedure, followed by immediate repair of the LCX, avoiding structural damage of the LV.

Conclusion

Cardioband implantation is accompanied by significant elevation of hsTnT without causing structural myocardial damage or clinical symptoms such as worsening of LV function, new-onset LV regions exhibiting reduced wall motion, or ventricular tachycardia.

Patel JB, Borgeson DD, Barnes ME, Rihal CS, Daly RC, Redfield MM (2004) Mitral regurgitation in patients with advanced systolic heart failure. J Card Fail 10(4):285–291CrossRefPubMed

Pleger ST, Schulz-Schonhagen M, Geis N, Mereles D, Chorianopoulos E, Antaredja M, Lewening M, Katus HA, Bekeredjian R (2013) One year clinical efficacy and reverse cardiac remodelling in patients with severe mitral regurgitation and reduced ejection fraction after MitraClip implantation. Eur J Heart Fail 15(8):919–927. https://doi.org/10.1093/eurjhf/hft046 CrossRefPubMed

Agricola E, Ielasi A, Oppizzi M, Faggiano P, Ferri L, Calabrese A, Vizzardi E, Alfieri O, Margonato A (2009) Long-term prognosis of medically treated patients with functional mitral regurgitation and left ventricular dysfunction. Eur J Heart Fail 11(6):581–587. https://doi.org/10.1093/eurjhf/hfp051 CrossRefPubMed

Kreusser MM, Tschierschke R, Beckendorf J, Baxmann T, Frankenstein L, Dosch AO, Schultz JH, Giannitsis E, Pleger ST, Ruhparwar A, Karck M, Katus HA, Raake PW (2018) The need for dedicated advanced heart failure units to optimize heart failure care: impact of optimized advanced heart failure unit care on heart transplant outcome in high-risk patients. ESC Heart Fail. https://doi.org/10.1002/ehf2.12314 CrossRefPubMedPubMedCentral

Feldman T, Foster E, Glower DD, Kar S, Rinaldi MJ, Fail PS, Smalling RW, Siegel R, Rose GA, Engeron E, Loghin C, Trento A, Skipper ER, Fudge T, Letsou GV, Massaro JM, Mauri L, Investigators EI (2011) Percutaneous repair or surgery for mitral regurgitation. N Engl J Med 364(15):1395–1406. https://doi.org/10.1056/NEJMoa1009355 CrossRefPubMed

Feldman T, Kar S, Elmariah S, Smart SC, Trento A, Siegel RJ, Apruzzese P, Fail P, Rinaldi MJ, Smalling RW, Hermiller JB, Heimansohn D, Gray WA, Grayburn PA, Mack MJ, Lim DS, Ailawadi G, Herrmann HC, Acker MA, Silvestry FE, Foster E, Wang A, Glower DD, Mauri L, Investigators EI (2015) Randomized comparison of percutaneous repair and surgery for mitral regurgitation: 5‑year results of EVEREST II. J Am Coll Cardiol 66(25):2844–2854. https://doi.org/10.1016/j.jacc.2015.10.018 CrossRefPubMed

Puls M, Lubos E, Boekstegers P, von Bardeleben RS, Ouarrak T, Butter C, Zuern CS, Bekeredjian R, Sievert H, Nickenig G, Eggebrecht H, Senges J, Schillinger W (2016) One-year outcomes and predictors of mortality after MitraClip therapy in contemporary clinical practice: results from the German transcatheter mitral valve interventions registry. Eur Heart J 37(8):703–712. https://doi.org/10.1093/eurheartj/ehv627 CrossRefPubMed

Rudolph V, Huntgeburth M, von Bardeleben RS, Boekstegers P, Lubos E, Schillinger W, Ouarrak T, Eggebrecht H, Butter C, Plicht B, May A, Franzen O, Schofer J, Senges J, Baldus S (2014) Clinical outcome of critically ill, not fully recompensated, patients undergoing MitraClip therapy. Eur J Heart Fail 16(11):1223–1229. https://doi.org/10.1002/ejhf.169 CrossRefPubMed

Zuern CS, Bauer A, Lubos E, Boekstegers P, Puls M, Bardeleben RS, Ouarrak T, Butter C, Eggebrecht H, Nickenig G, Zahn R, Senges J, May AE (2015) Influence of non-cardiac comorbidities on outcome after percutaneous mitral valve repair: results from the German transcatheter mitral valve interventions (TRAMI) registry. Clin Res Cardiol 104(12):1044–1053. https://doi.org/10.1007/s00392-015-0872-x CrossRefPubMed

10.

Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ, Iung B, Lancellotti P, Lansac E, Rodriguez Munoz D, Rosenhek R, Sjogren J, Tornos Mas P, Vahanian A, Walther T, Wendler O, Windecker S, Zamorano JL, Group ESCSD (2017) 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 38(36):2739–2791. https://doi.org/10.1093/eurheartj/ehx391 CrossRefPubMed

11.

Maisano F, Taramasso M, Nickenig G, Hammerstingl C, Vahanian A, Messika-Zeitoun D, Baldus S, Huntgeburth M, Alfieri O, Colombo A, La Canna G, Agricola E, Zuber M, Tanner FC, Topilsky Y, Kreidel F, Kuck KH (2016) Cardioband, a transcatheter surgical-like direct mitral valve annuloplasty system: early results of the feasibility trial. Eur Heart J 37(10):817–825. https://doi.org/10.1093/eurheartj/ehv603 CrossRefPubMed

12.

Nickenig G, Hammerstingl C, Schueler R, Topilsky Y, Grayburn PA, Vahanian A, Messika-Zeitoun D, Urena Alcazar M, Baldus S, Volker R, Huntgeburth M, Alfieri O, Latib A, La Canna G, Agricola E, Colombo A, Kuck KH, Kreidel F, Frerker C, Tanner FC, Ben-Yehuda O, Maisano F (2016) Transcatheter mitral annuloplasty in chronic functional mitral regurgitation: 6‑month results with the cardioband percutaneous mitral repair system. Jacc Cardiovasc Interv 9(19):2039–2047. https://doi.org/10.1016/j.jcin.2016.07.005 CrossRefPubMed

13.

Orban M, Braun D, Orban M, Gross L, Nabauer M, Hagl CM, Massberg S, Hausleiter J (2016) Established interventions for mitral valve regurgitation. Current evidence. Herz 41(1):19–25. https://doi.org/10.1007/s00059-015-4386-0 CrossRefPubMed

14.

Pleger ST, Mereles D, Schulz-Schonhagen M, Krumsdorf U, Chorianopoulos E, Rottbauer W, Katus HA, Bekeredjian R (2011) Acute safety and 30-day outcome after percutaneous edge-to-edge repair of mitral regurgitation in very high-risk patients. Am J Cardiol 108(10):1478–1482. https://doi.org/10.1016/j.amjcard.2011.06.069 CrossRefPubMed

15.

World Medical A (2013) World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 310(20):2191–2194. https://doi.org/10.1001/jama.2013.281053 CrossRef

16.

Geis N, Raake P, Lewening M, Mereles D, Chorianopoulos E, Frankenstein L, Katus HA, Bekeredjian R, Pleger ST (2017) Percutaneous repair of mitral valve regurgitation in patients with severe heart failure: comparison with optimal medical treatment. Acta Cardiol. https://doi.org/10.1080/00015385.2017.1401275 CrossRefPubMed

17.

Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Guyton RA, O’Gara PT, Ruiz CE, Skubas NJ, Sorajja P, Sundt TM 3rd, Thomas JD, American College of Cardiology, American Heart Association Task Force on Practice G (2014) 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63(22):e57–e185. https://doi.org/10.1016/j.jacc.2014.02.536 CrossRefPubMed

18.

Zoghbi WA, Enriquez-Sarano M, Foster E, Grayburn PA, Kraft CD, Levine RA, Nihoyannopoulos P, Otto CM, Quinones MA, Rakowski H, Stewart WJ, Waggoner A, Weissman NJ, American Society of E (2003) Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr 16(7):777–802. https://doi.org/10.1016/S0894-7317(03)00335-3 CrossRefPubMed

19.

Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ, Chamber Quantification Writing G, American Society of Echocardiography’s G, Standards C, European Association of E (2005) Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography 18 (12):1440–1463. https://doi.org/10.1016/j.echo.2005.10.005 CrossRef

20.

Ganz W (1985) The thrombolysis in myocardial infarction (TIMI) trial. N Engl J Med 313(16):1018. https://doi.org/10.1056/NEJM198510173131611 CrossRefPubMed

21.

Chorianopoulos E, Krumsdorf U, Geis N, Pleger ST, Giannitsis E, Katus HA, Bekeredjian R (2014) Preserved prognostic value of preinterventional troponin T levels despite successful TAVI in patients with severe aortic stenosis. Clin Res Cardiol 103(1):65–72. https://doi.org/10.1007/s00392-013-0624-8 CrossRefPubMed

22.

Liebetrau C, Kim WK, Meyer A, Arsalan M, Gaede L, Blumenstein JM, Fischer-Rasokat U, Wolter JS, Dorr O, Schillinger S, Troidl C, Nef HM, Hamm CW, Walther T, Mollmann H (2017) Identification of periprocedural myocardial infarction using a high-sensitivity troponin I assay in patients who underwent transcatheter aortic valve implantation. Am J Cardiol 120(7):1180–1186. https://doi.org/10.1016/j.amjcard.2017.06.069 CrossRefPubMed

23.

Yoshida K, Yui Y, Kimata A, Koda N, Kato J, Baba M, Misaki M, Abe D, Tokunaga C, Akishima S, Sekiguchi Y, Tada H, Aonuma K, Takeyasu N (2014) Troponin elevation after radiofrequency catheter ablation of atrial fibrillation: relevance to AF substrate, procedural outcomes, and reverse structural remodeling. Heart Rhythm 11(8):1336–1342. https://doi.org/10.1016/j.hrthm.2014.04.015 CrossRefPubMed

24.

Herrera Siklody C, Arentz T, Minners J, Jesel L, Stratz C, Valina CM, Weber R, Kalusche D, Toti F, Morel O, Trenk D (2012) Cellular damage, platelet activation, and inflammatory response after pulmonary vein isolation: a randomized study comparing radiofrequency ablation with cryoablation. Heart Rhythm 9(2):189–196. https://doi.org/10.1016/j.hrthm.2011.09.017 CrossRefPubMed

25.

McCarthy CP, Donnellan E, Phelan D, Griffin BP, Enriquez-Sarano M, McEvoy JW (2017) High sensitivity troponin and valvular heart disease. Trends Cardiovasc Med 27(5):326–333. https://doi.org/10.1016/j.tcm.2017.01.004 CrossRefPubMed

26.

Solberg OG, Ueland T, Wergeland R, Dahl CP, Aakhus S, Aukrust P, Gullestad L (2012) High-sensitive troponin T and N‑terminal-brain-natriuretic-peptide predict outcome in symptomatic aortic stenosis. Scand Cardiovasc J 46(5):278–285. https://doi.org/10.3109/14017431.2012.687836 CrossRefPubMed

27.

Kohler WM, Freitag-Wolf S, Lambers M, Lutz M, Niemann PM, Petzina R, Lutter G, Bramlage P, Frey N, Frank D (2016) Preprocedural but not periprocedural high-sensitive Troponin T levels predict outcome in patients undergoing transcatheter aortic valve implantation. Cardiovasc Ther 34(6):385–396. https://doi.org/10.1111/1755-5922.12208 CrossRefPubMed

28.

Saunders JT, Nambi V, de Lemos JA, Chambless LE, Virani SS, Boerwinkle E, Hoogeveen RC, Liu X, Astor BC, Mosley TH, Folsom AR, Heiss G, Coresh J, Ballantyne CM (2011) Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities Study. Circulation 123(13):1367–1376. https://doi.org/10.1161/CIRCULATIONAHA.110.005264 CrossRefPubMedPubMedCentral

29.

Egstrup M, Schou M, Tuxen CD, Kistorp CN, Hildebrandt PR, Gustafsson F, Faber J, Goetze JP, Gustafsson I (2012) Prediction of outcome by highly sensitive troponin T in outpatients with chronic systolic left ventricular heart failure. Am J Cardiol 110(4):552–557. https://doi.org/10.1016/j.amjcard.2012.04.033 CrossRefPubMed

30.

Scheven L, de Jong PE, Hillege HL, Lambers Heerspink HJ, van Pelt LJ, Kootstra JE, Bakker SJ, Gansevoort RT, group Ps (2012) High-sensitive troponin T and N‑terminal pro-B type natriuretic peptide are associated with cardiovascular events despite the cross-sectional association with albuminuria and glomerular filtration rate. Eur Heart J 33(18):2272–2281. https://doi.org/10.1093/eurheartj/ehs163 CrossRefPubMed

Titel: Transient elevation of high-sensitive troponin T after Cardioband implantation
verfasst von: M. M. Kreusser, MD
S. T. Pleger, MD
H. Abu Sharar, MD
N. A. Geis, MD
R. Bekeredjian, MD
H. A. Katus, MD
P. W. Raake, MD
Publikationsdatum: 25.09.2018
Verlag: Springer Medizin
Erschienen in: Herz / Ausgabe 6/2019
Print ISSN: 0340-9937
Elektronische ISSN: 1615-6692
DOI: https://doi.org/10.1007/s00059-018-4754-7

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Background

Methods and results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2019

COPD and heart failure: differential diagnosis and comorbidity

Schwerwiegende unerwünschte Ereignisse in klinischen Prüfungen mit TAVR und SAVR

Pulmonary and cardiac drugs: clinically relevant interactions

Right ventricular function in pulmonary (arterial) hypertension